Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit- Hagens Berman

Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit- Hagens Berman IOVA Investors with Losses Encouraged to Contact Hagens Berman GlobeNewswire June 04, 2025 SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its […]

Compass Diversified (CODI) Grapples with Financial Irregularities, Slashes Dividend Amid Investor Lawsuit – Hagens Berman

(NYSE:CODI), SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — Shares of Compass Diversified (NYSE: CODI) plunged nearly 15 percent in intraday Wednesday trading, as the private equity firm scrambled to shore up its finances following the discovery of troubling accounting practices at one of its subsidiaries, which has sparked a securities class action. Hagens Berman

INVESTOR ALERT: Investigation of Abacus Global Management, Inc. (ABL) Announced by Holzer & Holzer, LLC

(NASDAQ:ABL), ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL) complied with federal securities laws. On June 4, 2025, Morpheus Research published a report alleging that Abacus's returns “are primarily manufactured by the systematic overvaluation of its assets through an

Compass Diversified (CODI) Grapples with Financial Irregularities, Slashes Dividend Amid Investor Lawsuit – Hagens Berman

Compass Diversified (CODI) Grapples with Financial Irregularities, Slashes Dividend Amid Investor Lawsuit – Hagens Berman CODI Investors with Losses Encouraged to Contact Hagens Berman GlobeNewswire June 04, 2025 SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — Shares of Compass Diversified (NYSE: CODI) plunged nearly 15 percent in intraday Wednesday trading, as the private equity firm

INVESTOR ALERT: Investigation of Abacus Global Management, Inc. (ABL) Announced by Holzer & Holzer, LLC

INVESTOR ALERT: Investigation of Abacus Global Management, Inc. (ABL) Announced by Holzer & Holzer, LLC GlobeNewswire June 04, 2025 ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL) complied with federal securities laws. On June 4, 2025, Morpheus Research published

BigBear.ai Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff Motion

(NYSE:BBAI), Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises BigBear.ai Holdings, Inc. (“BigBear ” or the “Company”) (NYSE: BBAI) investors of a class action representing investors that bought securities between March 31, 2022 and

BigBear.ai Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff Motion

BigBear.ai Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire June 04, 2025 Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman

(NasdaqGM:URGN), SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025. The lawsuit comes after investors saw

Northern Ireland Department of Education To Launch Research Study to Evaluate AI’s Role in Advancing Literacy for Students

Researchinitiative, led by Oxford Brookes University (OBU) and using Amira, willevaluate evidence-based AI reading interventions to support students andinform national literacy policy Today, the Northern Ireland Department of Educationannounced it will fund a national research studyto evaluate the impact of AI-powered literacy interventions on reading outcomes with Amira Learning (Amira), particularly for disadvantaged pupils and

CSI Pharmacy Secures California Non-Resident Permit, Achieving Nationwide Reach

Bringing Personalized Specialty Pharmacy Services to All 50 States CSI Pharmacy is proud to reveal that, as of May 13, 2025, it is officially licensed to serve patients in all 50 states with the approval of two non-resident California pharmacy permits. This milestone marks a major achievement in CSI Pharmacy's mission to deliver personalized, patient-centered

Scroll to Top